A. Martinez

TL;DR: Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment, and a multivariate model created from three gene-expression signatures predicted survival both in patients who received CHOP and patients who receive R-CHOP.

TL;DR: FLIPI and histology were the most important variables predicting HT, and only patients achieving CR reached prolonged survival, thus emphasizing the need for effective therapies once this event occurs.

TL;DR: It is shown that ZEB1, a transcription factor better known for promoting metastasis in carcinomas, is expressed in primary MCLs with active Wnt signaling, and this gene could potentially become a predictive biomarker and therapeutic target in this lymphoma.

TL;DR: It is suggested that exacerbated IRF4/MYC signaling is associated to bortezomib resistance in MCL in vivo and warrant clinical evaluation of lenalidomide plus BET inhibitor combination in Mcl cases refractory to proteasome inhibition.

TL;DR: All the scores demonstrated their usefulness to assess the outcome of patients with PTCL, with IPTCLP being the most significant to predict OS.